| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Over the last 12 months, insiders at VYNE Therapeutics Inc. have bought $0 and sold $0 worth of VYNE Therapeutics Inc. stock.
On average, over the past 5 years, insiders at VYNE Therapeutics Inc. have bought $3.42M and sold $5.32M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $43,800 was made by LEPORE PATRICK G (director) on 2025‑01‑15.
| 2025-01-15 | LEPORE PATRICK G | director | 15,000 0.106% | $2.92 | $43,800 | -66.38% | ||
| 2023-11-15 | LEPORE PATRICK G | director | 13,000 0.3748% | $3.91 | $50,778 | -45.75% | ||
| 2021-11-30 | LEPORE PATRICK G | director | 12,500 0.024% | $1.02 | $12,699 | -55.58% | ||
| 2021-08-25 | LEPORE PATRICK G | director | 12,500 0.0243% | $1.60 | $20,000 | -62.27% | ||
| 2021-08-16 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 250,000 0.4697% | $1.74 | $435,000 | -64.78% | |
| 2021-08-13 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 250,000 0.4967% | $1.84 | $460,000 | -64.61% | |
| 2021-08-12 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 338,897 0.7299% | $2.23 | $755,740 | -68.34% | |
| 2021-05-26 | LEPORE PATRICK G | director | 12,500 0.0241% | $3.60 | $44,958 | -68.32% | ||
| 2021-05-06 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 1M 2.0052% | $3.67 | $3.67M | -65.17% | |
| 2021-03-15 | LEPORE PATRICK G | director | 12,500 0.0259% | $7.41 | $92,563 | -79.34% | ||
| 2021-01-28 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 4.22M 2.2941% | $2.37 | $10M | -69.62% | ||
| 2020-12-03 | LEPORE PATRICK G | director | 100,000 0.078% | $1.71 | $170,850 | -46.15% | ||
| 2020-09-08 | Domzalski David | President and CEO | 150,000 0.084% | $1.38 | $207,135 | +10.54% | ||
| 2020-09-08 | Saik Andrew | Chief Financial Officer | 80,000 0.0474% | $1.46 | $116,960 | +10.54% | ||
| 2020-06-09 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 5.41M 3.4508% | $1.85 | $10M | -19.14% | ||
| 2018-07-24 | Sale | Presidio Partners 2007 GP, L.P. | 1M 4.3407% | $7.65 | $7.65M | -11.34% | ||
| 2018-01-25 | Remeditex Ventures LLC | 10 percent owner | 200,000 0.6735% | $17.00 | $3.4M | -71.72% | ||
| 2018-01-25 | venBio Global Strategic Fund II L.P. | 10 percent owner | 530,000 1.7848% | $17.00 | $9.01M | -71.72% | ||
| 2018-01-25 | Vivo Capital VIII, LLC | 10 percent owner | 588,236 1.9809% | $17.00 | $10M | -71.72% | ||
| 2018-01-25 | Cha Albert | director | 588,236 1.9809% | $17.00 | $10M | -71.72% |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 4935057 29.6135% | $2.8M | 2 | 4 | <0.0001% |
| Remeditex Ventures LLC | 10 percent owner | 1582854 9.4981% | $897,161.65 | 1 | 0 | |
| Domzalski David | President and CEO | 1315966 7.8966% | $745,889.53 | 1 | 0 | +10.54% |
| Saik Andrew | Chief Financial Officer | 340000 2.0402% | $192,712.00 | 1 | 0 | +10.54% |
| venBio Global Strategic Fund II L.P. | 10 percent owner | 265000 1.5902% | $150,202.00 | 1 | 0 | |
| Cha Albert | director | 258432 1.5508% | $146,479.26 | 1 | 0 | |
| Vivo Capital VIII, LLC | 10 percent owner | 258432 1.5508% | $146,479.26 | 1 | 0 | |
| LEPORE PATRICK G | director | 51472 0.3089% | $29,174.33 | 7 | 0 | <0.0001% |
| Presidio Partners 2007 GP, L.P. | 48910 0.2935% | $27,722.19 | 0 | 1 |
$1,848,072 | 66 | -14.67% | $10.21M | |
$13,664,154 | 40 | -70.35% | $7.38M | |
$226,127 | 22 | -27.62% | $10.27M | |
$947,115 | 15 | -7.40% | $8.12M | |
$4,146,041 | 11 | -40.86% | $10.22M | |
$188,726 | 11 | -28.87% | $9M | |
VYNE Therapeutics Inc. (VYNE) | $20,715,938 | 10 | -42.51% | $9.45M |
$120,379 | 10 | -24.48% | $7.94M | |
$11,777,042 | 10 | -11.94% | $9.59M | |
$3,885,120 | 9 | -38.33% | $10.7M | |
$241,042 | 9 | -11.02% | $11.46M | |
$211,895 | 8 | -39.70% | $7.05M | |
$159,974 | 7 | -18.60% | $6.97M | |
$192,099 | 7 | -39.17% | $8.02M | |
$7,268,979 | 7 | -48.44% | $9.5M | |
$2,060,158 | 5 | -21.35% | $11.38M | |
$1,184,658 | 4 | -22.17% | $9.59M | |
$76,299 | 4 | 11.60% | $7.93M | |
$1,057,000 | 3 | 5.27% | $7.66M |
| Increased Positions | 15 | +23.44% | 2M | +27.35% |
| Decreased Positions | 24 | -37.5% | 6M | -77.95% |
| New Positions | 8 | New | 2M | New |
| Sold Out Positions | 19 | Sold Out | 6M | Sold Out |
| Total Postitions | 55 | -14.06% | 4M | -50.61% |
| Baker Bros. Advisors Lp | $494.00 | 2.58% | 851,353 | +851,353 | New | 2025-09-30 |
| Acorn Capital Advisors, Llc | $340.00 | 1.78% | 586,572 | -150,000 | -20.36% | 2025-09-30 |
| Shay Capital Llc | $286.00 | 1.49% | 492,577 | +492,577 | New | 2025-09-30 |
| Acadian Asset Management Llc | $259.00 | 1.35% | 446,414 | +423,996 | +1,891.32% | 2025-09-30 |
| Ikarian Capital, Llc | $168.00 | 0.88% | 290,000 | 0 | 0% | 2025-09-30 |
| Two Sigma Investments, Lp | $128.00 | 0.67% | 220,788 | +220,788 | New | 2025-09-30 |
| Vanguard Group Inc | $110.00 | 0.58% | 190,383 | -305,914 | -61.64% | 2025-09-30 |
| Jane Street Group, Llc | $85.00 | 0.45% | 147,120 | +22,298 | +17.86% | 2025-09-30 |
| Geode Capital Management, Llc | $80.00 | 0.42% | 137,122 | +3,793 | +2.85% | 2025-09-30 |
| Boothbay Fund Management, Llc | $62.00 | 0.32% | 106,459 | 0 | 0% | 2025-09-30 |